Jim Tananbaum Brings Foresite Capital into the Next Level with Addition of Renowned Biochemist
Dr. Jim Tananbaum is one of the most prolific healthcare venture capitalist, entrepreneur, and investor in the United States today. He is credited with founding three of the most successful healthcare companies over a career spanning 25 years. Tananbaum received his BS and BSEE in Applied Math and Computer Science from Yale University, before receiving his MS degree from MIT, as well as MD and MBA degrees from Harvard.
Dr. Jim Tananbaum has an illustrious entrepreneurial history. He started out as a founding partner at Sierra Ventures and Prospect Venture Partners. While still finishing his postgraduate studies at Harvard and MIT, Jim founded GelTex Pharmaceuticals. This venture introduced two new drugs into the market for about 80 million dollars but was eventually acquired by Sanofi-Genzyme in 1998 for 1.6 billion dollars.
He also was the co-founder and CEO of respiratory franchise Theravance Inc., which later changed its name to Innoviva Inc. Along with the spinoff company Theravance Biophama, these two ventures have a total market capitalization of about 3.2 billion dollars today. He has also led various other investments including Amira Pharmaceuticals, Amerigroup, Jazz Pharmaceuticals, and Healtheon.
In 2011, Jim went on to establish Foresite Capital with the aim of creating a unique platform for investments. He currently serves as its Chief Executive Officer and Managing Director. Foresite Capital works with leading emerging public and private sector companies in healthcare to provide them with growth capital. The firm has its headquarters in San Francisco, as well as offices in New York.
In April this year, Foresite Capital announced the addition of Molly He, PhD., to their team of venture partners. Dr. He has accumulated over 15 years’ experience in genomic, as well as the development of new drugs. She is a renowned researchers in genomics and drug development and learn more about Jim.
While welcoming Dr. He, Dr. Tananbaum praised her excellent track record in leadership. He also stated that she will be invaluable to the firm as they keep expanding and diversifying their portfolio of companies and Jim’s lacrosse camp.
Previously, Dr. He headed the scientific research team at Illumina, where she oversaw the company’s innovations in global protein reagents. She also served as the oversaw the protein sciences department at Pacific Biosciences. Further, Dr. He worked for over ten years in structural-based antibody design and research into new cancer therapies.
She studied Biochemistry in China’s Nankai University, where she received her bachelors’ degree. She also holds a Ph.D. from the University of California, where her specialization was in the biophysics of proteins. Further, she has authored numerous acclaimed papers in personalized medicine and next-gen sequencing, and is the holder of over 20 patents and Jim of Facebook.